GGCT Inhibitors

Acivicin inhibits the enzyme gamma-glutamyltransferase (GGT), which shares a similar gamma-glutamyl cycle with GGCT. Inhibition of GGT can lead to a buildup of gamma-glutamyl compounds, which may competitively inhibit GGCT, preventing its normal enzymatic activity of cleaving gamma-glutamyl peptide bonds.

This proline analog can be mistakenly incorporated into proteins in place of proline, potentially disrupting protein folding and function. As GGCT is involved in the catabolism of glutathione which contains glutamate, the misincorporation could disrupt the protein structure and thus inhibit GGCT activity.

Buthionine sulfoximine is an inhibitor of gamma-glutamylcysteine synthetase. By inhibiting this enzyme, the synthesis of glutathione is blocked, potentially leading to altered levels of substrates or products in the gamma-glutamyl cycle, which could inhibit the activity of GGCT by substrate depletion.

Methotrexate acts as a competitive inhibitor of dihydrofolate reductase, leading to decreased purine synthesis. As cellular proliferation and metabolism can affect enzyme function, reduced purine levels might indirectly inhibit GGCT by altering the pool of gamma-glutamyl amino acids, thereby affecting its activity.

Azaserine is a glutamine antagonist that inhibits glutamine-utilizing enzymes, similar to DON. By inhibiting these enzymes, it could lead to an accumulation or depletion of glutamine or its related metabolites, which might hinder the enzymatic cycle in which GGCT operates, resulting in its functional inhibition.

Cisplatin forms DNA adducts and crosslinks, which can trigger various cellular stress responses. One of these responses includes the alteration of metabolic pathways, which could inhibit GGCT through the modulation of cellular redox states and glutathione levels, as GGCT is involved in glutathione metabolism.

Ethacrynic acid is known to inhibit glutathione S-transferases, and by extension, could influence glutathione metabolism. Such an influence might lead to altered glutathione levels or its precursors, potentially inhibiting GGCT function due to changes in its substrate availability.

Chloroquine raises endosomal pH and can affect cellular autophagy and lysosomal function. As GGCT is associated with glutathione metabolism, the alteration in autophagy and lysosomal degradation pathways could lead to disruptions in amino acid recycling, indirectly inhibiting GGCT by affecting the availability of its substrates.

Ebselen is a seleno-organic compound that exhibits glutathione peroxidase-like activity. By mimicking this enzyme, ebselen could potentially disrupt the balance of glutathione metabolism, leading to either a depletion or an imbalance of glutathione or glutathione-related metabolites, which might inhibit the function of GGCT.